This article was originally published in Start Up
CardiacAssist has gotten off the beaten path of ventricular assist device companies (VAD) vying for a piece of the congestive heart failure market. It is positioning its own implantable VAD as a percutaneous device that can serve the needs of cardiogenic shock patients, by bridging them to therapeutic interventions.
You may also be interested in...
CardiacAssist operates in the market for acute heart failure, with TandemHeart a pump designed to reverse multi-organ failure, to help the heart recover, or at the very least, keep patients alive so they can move on to the next therapeutic option. A lot has happened since Start-Up spoke with CardiacAssist back in 2002. The company's TandemHeart gained 510(k) clearance in 2003, and by January 2009, more than 1,500 TandemHeart procedures had been performed. The pace of adoption is accelerating. Now, with sales of $10 million, and a steady 40% growth rate, the company is no longer dependent upon venture capital.
Looking for larger patient populations, the newer CHF device companies position their products as early intervention tools that can perhaps delay or halt the progression of the disease.
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.